The development of Chimeric Antigen Receptor T-cell (CAR-T) therapies continues to challenge traditional pharmaceutical manufacturing models. Unlike conventional drugs, CAR-T products are complex cellular therapies with patient-specific or donor-derived starting materials, highly variable biological processes, and manufacturing steps that can directly influence product quality and clinical performance. In 2026, the U.S. Food and Drug Administration (FDA) further clarified its approach to Chemistry, Manufacturing, and Controls (CMC) requirements for cellular and gene therapy products, introducing greater flexibility during development while maintaining expectations for product quality, safety, identity, purity, and potency.

The FDA’s May 2026 final guidance, Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application, explains when CMC flexibilities may be appropriate for cellular and gene therapy products being developed toward a Biologics License Application (BLA). The framework recognizes that manufacturing processes and analytical methods for these products often evolve during development. FDA states that its flexible approach is intended to help expedite development and review while ensuring applicable regulatory requirements are met.

For CAR-T manufacturing compliance, this represents an important shift toward a lifecycle-based approach. Sponsors do not necessarily need to finalize every manufacturing control, specification, or validation activity at the earliest stage of development. Instead, the level of CMC development should be appropriate to the stage of clinical development, with manufacturing knowledge and controls strengthened as the product advances toward licensure. FDA specifically notes that process and method validation can be addressed using a product lifecycle approach in which validation strategies are refined over time.

This flexibility does not eliminate the need for strong manufacturing controls. CAR-T manufacturing involves multiple steps, including cell collection, selection or activation, genetic modification, expansion, formulation, and final product testing. Each step can introduce variability that may affect critical quality attributes (CQAs). FDA’s CAR-T guidance recommends controlling the manufacturing process through appropriate materials, process controls, in-process testing, and testing of intermediates and the final product as appropriate for the development stage.

Raw materials and manufacturing components also require careful oversight. CAR-T processes may use specialized reagents, cytokines, growth factors, antibodies, and other materials whose quality can vary by source or supplier. Sponsors should establish appropriate qualification and control strategies based on the potential impact of each material on product quality and patient safety. FDA’s broader CGT recommendations also address risks associated with human- and animal-derived materials, including adventitious agents, material consistency, and identity.

Potency remains a particularly important consideration for CAR-T products. Because the therapeutic activity depends on complex biological mechanisms, sponsors should develop scientifically justified potency assays and demonstrate how these assays relate to the intended biological activity of the product. The analytical strategy should evolve as product and process understanding increases, while maintaining appropriate controls to support reliable characterization and release decisions.

Manufacturing changes present another major regulatory consideration. CAR-T developers frequently modify processes, facilities, equipment, raw materials, analytical methods, or manufacturing sites during development. FDA’s lifecycle approach to CGT manufacturing changes emphasizes assessing whether a change could affect product quality and using appropriate comparability studies to understand its impact. A well-defined change management strategy is therefore essential for maintaining control as manufacturing evolves.

The new flexibility also increases the importance of a scientifically justified CMC strategy. Sponsors should identify critical process parameters, CQAs, sources of variability, manufacturing risks, and appropriate control strategies early in development. Rather than generating data simply to satisfy a checklist, manufacturers should focus on building sufficient process understanding to demonstrate that the product can be consistently manufactured with the required quality characteristics.

For organizations preparing for a BLA, the challenge is balancing regulatory flexibility with manufacturing maturity. FDA’s 2026 guidance makes clear that flexibility is intended to facilitate development, but it does not comprehensively address all CMC information required for licensure. Sponsors should therefore establish a development plan that progressively strengthens process validation, analytical methods, specifications, facility controls, material qualification, comparability, and overall manufacturing readiness.

Ultimately, the FDA’s 2026 CMC framework provides CAR-T developers with greater flexibility to manage the realities of complex cell therapy development while maintaining a strong focus on product quality and patient safety. Organizations that combine regulatory flexibility with disciplined process control, lifecycle management, analytical development, and robust quality systems will be better positioned to advance CAR-T products efficiently toward BLA submission and commercialization.